Codexis
CDXS | NASDAQ
$1.04
-$0.12 (-10.34%)
At close: Nov 16, 2026, 3:59 PM ET
$1.01
-$0.03 (-2.88%)
After-hours:
Nov 16, 2026, 7:30 PM ET
Codexis Company Profile
Company profile explainedCompany Profile
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
Key Executives
| Name | Position |
|---|---|
| Alison Moore | President, Chief Executive Officer & Director |
| Georgia L. Erbez | Chief Financial Officer & Chief Business Officer |
| Britton Jimenez | Senior Vice President of Sales & Marketing |
| John Schiffhauer | Senior Vice President of Intellectual Property |
| Karen Frechou-Armijo | Senior Vice President & Head of Human Resources |
| Stefan Lutz | Chief Scientific Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 30, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Oct 14, 2026 | 4 | Filing |
| Oct 14, 2026 | 4 | Filing |
| Aug 13, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Jul 29, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Jul 27, 2026 | 8-K | Current Report |
| Jul 24, 2026 | 424B5 | Filing |
| Jul 23, 2026 | 424B5 | Filing |
Codexis
| Country | United States |
| IPO Date | Apr 22, 2010 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 146 |
| CEO | Alison Moore |
Contact Details
200 Penobscot Drive Redwood City,
California 94063 United States
Stock Details
| Ticker Symbol | CDXS |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001200375 |
| CUSIP Number | 192005106 |
| ISIN Number | US1920051067 |
| SIC Code | 2860 |
Add to Watchlist
Select watchlists to add or remove CDXS